Hippocampal Hyperactivity as a Druggable Circuit-Level Origin of Aberrant Salience in Schizophrenia
暂无分享,去创建一个
[1] R. Douglas,et al. The hippocampus and behavior. , 1967, Psychological bulletin.
[2] S. Gershon,et al. Amphetamine psychosis: behavioral and biochemical aspects. , 1974, Journal of psychiatric research.
[3] G. P. Smith,et al. Efferent connections and nigral afferents of the nucleus accumbens septi in the rat , 1978, Neuroscience.
[4] E. Azmitia. The neuropsychology of anxiety: an enquiry into the functions of the Septo-Hippocampal system, Gray J.A.. Oxford University Press, New York (1981), pp. 523.,£27.50 , 1983 .
[5] G. Mogenson,et al. Electrophysiological responses of neurones in the nucleus accumbens to hippocampal stimulation and the attenuation of the excitatory responses by the mesolimbic dopaminergic system , 1984, Brain Research.
[6] G. Mogenson,et al. An electrophysiological study of the neural projections from the hippocampus to the ventral pallidum and the subpallidal areas by way of the nucleus accumbens , 1985, Neuroscience.
[7] G. Mogenson,et al. Dopamine enhances terminal excitability of hippocampal-accumbens neurons via D2 receptor: role of dopamine in presynaptic inhibition , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[8] G. Mogenson,et al. Hippocampal signal transmission to the pedunculopontine nucleus and its regulation by dopamine D2 receptors in the nucleus accumbens: An electrophysiological and behavioural study , 1987, Neuroscience.
[9] Robert Miller,et al. Hyperactivity of Associations in Psychosis , 1989, The Australian and New Zealand journal of psychiatry.
[10] N. Swerdlow,et al. GABAergic projection from nucleus accumbers to ventral pallidum mediates dopamine-induced sensorimotor gating deficits of acoustic startle in rats , 1990, Brain Research.
[11] J. Rawlins,et al. The neuropsychology of schizophrenia , 1991, Behavioral and Brain Sciences.
[12] A. Grace. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia , 1991, Neuroscience.
[13] W. Schultz,et al. Responses of monkey dopamine neurons during learning of behavioral reactions. , 1992, Journal of neurophysiology.
[14] W. Schultz,et al. Neuronal activity in monkey ventral striatum related to the expectation of reward , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[15] W. Schultz,et al. Neuronal activity in monkey striatum related to the expectation of predictable environmental events. , 1992, Journal of neurophysiology.
[16] N. Swerdlow,et al. Accumbens D2 modulation of sensorimotor gating in rats: Assessing anatomical localization , 1994, Pharmacology Biochemistry and Behavior.
[17] M Spitzer,et al. A neurocomputational approach to delusions. , 1995, Comprehensive psychiatry.
[18] Paul J. Harrison,et al. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. , 1995, Brain research. Molecular brain research.
[19] P. Dayan,et al. A framework for mesencephalic dopamine systems based on predictive Hebbian learning , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[20] Peter Dayan,et al. A Neural Substrate of Prediction and Reward , 1997, Science.
[21] S. Floresco,et al. Stimulation of the Ventral Subiculum of the Hippocampus Evokes Glutamate Receptor‐mediated Changes in Dopamine Efflux in the Rat Nucleus Accumbens , 1997, The European journal of neuroscience.
[22] J. Pin,et al. Pharmacology and functions of metabotropic glutamate receptors. , 1997, Annual review of pharmacology and toxicology.
[23] R. C. Honey,et al. Hippocampal Lesions Disrupt an Associative Mismatch Process , 1998, The Journal of Neuroscience.
[24] N. Alpert,et al. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia , 1998, Nature Neuroscience.
[25] Robert Miller,et al. A Rating Scale for Psychotic Symptoms (RSPS) Part I: theoretical principles and subscale 1: perception symptoms (illusions and hallucinations) , 1999, Schizophrenia Research.
[26] J. Gorman,et al. SPECT study of visual fixation in schizophrenia and comparison subjects , 1999, Biological Psychiatry.
[27] R. Wise,et al. Injections of N‐methyl‐D‐aspartate into the ventral hippocampus increase extracellular dopamine in the ventral tegmental area and nucleus accumbens , 1999, Synapse.
[28] J. Lieberman,et al. Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization , 1999, Molecular Psychiatry.
[29] S. Floresco,et al. Hyperlocomotion and increased dopamine efflux in the rat nucleus accumbens evoked by electrical stimulation of the ventral subiculum: role of ionotropic glutamate and dopamine D1 receptors , 2000, Psychopharmacology.
[30] J. Rawlins,et al. Activation of the retrohippocampal region in the rat causes dopamine release in the nucleus accumbens: disruption by fornix section. , 2000, European journal of pharmacology.
[31] J. Horvitz. Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events , 2000, Neuroscience.
[32] Daniel R Weinberger,et al. To Model a Psychiatric Disorder in Animals: Schizophrenia As a Reality Test , 2000, Neuropsychopharmacology.
[33] R. Wise,et al. Chemical Stimulation of the Ventral Hippocampus Elevates Nucleus Accumbens Dopamine by Activating Dopaminergic Neurons of the Ventral Tegmental Area , 2000, The Journal of Neuroscience.
[34] A. Grace,et al. Glutamatergic Afferents from the Hippocampus to the Nucleus Accumbens Regulate Activity of Ventral Tegmental Area Dopamine Neurons , 2001, The Journal of Neuroscience.
[35] J. Lisman,et al. Hippocampus as comparator: Role of the two input and two output systems of the hippocampus in selection and registration of information , 2001, Hippocampus.
[36] R. Wise,et al. Novelty‐evoked elevations of nucleus accumbens dopamine: dependence on impulse flow from the ventral subiculum and glutamatergic neurotransmission in the ventral tegmental area , 2001, The European journal of neuroscience.
[37] J. Feldon,et al. Hyperactivity and disruption of prepulse inhibition induced by N-methyl-d-aspartate stimulation of the ventral hippocampus and the effects of pretreatment with haloperidol and clozapine , 2001, Neuroscience.
[38] H. Holcomb,et al. Probing the human hippocampus using rCBF: Contrasts in schizophrenia , 2001, Hippocampus.
[39] N. Swerdlow,et al. Measurement of Startle Response, Prepulse Inhibition, and Habituation , 1998, Current protocols in neuroscience.
[40] J. Feldon,et al. The ventral hippocampus and fear conditioning in rats , 2001, Experimental Brain Research.
[41] Gary Remington,et al. Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient , 2001, Biological Psychiatry.
[42] Franz X. Vollenweider,et al. Stability of the acoustic startle reflex, prepulse inhibition, and habituation in schizophrenia , 2002, Schizophrenia Research.
[43] G. Aston-Jones,et al. Activation of Ventral Tegmental Area Cells by the Bed Nucleus of the Stria Terminalis: A Novel Excitatory Amino Acid Input to Midbrain Dopamine Neurons , 2002, The Journal of Neuroscience.
[44] R. Palmiter,et al. Viral restoration of dopamine to the nucleus accumbens is sufficient to induce a locomotor response to amphetamine , 2003, Brain Research.
[45] H. Schroeder,et al. Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[46] S. Kapur. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. , 2003, The American journal of psychiatry.
[47] Diogo R. Lara,et al. Effect of Riluzole on MK-801 and Amphetamine-Induced Hyperlocomotion , 2003, Neuropsychobiology.
[48] A. Phillips,et al. Electrical stimulation of the hippocampus disrupts prepulse inhibition in rats: frequency- and site-dependent effects , 2004, Behavioural Brain Research.
[49] R. C. Honey,et al. Hippocampal lesions modulate both associative and nonassociative priming. , 2004, Behavioral neuroscience.
[50] J. Rawlins,et al. Medial septal lesions mimic effects of both selective dorsal and ventral hippocampal lesions. , 2004, Behavioral neuroscience.
[51] N. Swerdlow,et al. Schizophrenic-like sensorimotor gating abnormalities in rats following dopamine infusion into the nucleus accumbens , 2005, Psychopharmacology.
[52] Jonathan D. Cohen,et al. An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. , 2005, Annual review of neuroscience.
[53] N. Swerdlow,et al. Intra-accumbens infusion of quinpirole impairs sensorimotor gating of acoustic startle in rats , 2005, Psychopharmacology.
[54] Angela J. Yu,et al. Uncertainty, Neuromodulation, and Attention , 2005, Neuron.
[55] R. Palmiter,et al. Dopamine is not Required for the Hyperlocomotor Response to NMDA Receptor Antagonists , 2005, Neuropsychopharmacology.
[56] Cheryl A. Murphy,et al. Activation of dopaminergic neurotransmission in the medial prefrontal cortex by N-methyl-d-aspartate stimulation of the ventral hippocampus in rats , 2005, Neuroscience.
[57] Stephan Heckers,et al. Sustained activation of the hippocampus in response to fearful faces in schizophrenia , 2005, Biological Psychiatry.
[58] N. Swerdlow,et al. Regionally selective effects of intracerebral dopamine infusion on sensorimotor gating of the startle reflex in rats , 2005, Psychopharmacology.
[59] Anthony A Grace,et al. The Hippocampus Modulates Dopamine Neuron Responsivity by Regulating the Intensity of Phasic Neuron Activation , 2006, Neuropsychopharmacology.
[60] A. Grace,et al. The laterodorsal tegmentum is essential for burst firing of ventral tegmental area dopamine neurons. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[61] Arno Villringer,et al. Dysfunction of ventral striatal reward prediction in schizophrenia , 2006, NeuroImage.
[62] Stephan Heckers,et al. Increased medial temporal lobe activation during the passive viewing of emotional and neutral facial expressions in schizophrenia , 2006, Schizophrenia Research.
[63] J. Gogos,et al. Modeling Madness in Mice: One Piece at a Time , 2006, Neuron.
[64] Robert P. Vertes,et al. Interactions among the medial prefrontal cortex, hippocampus and midline thalamus in emotional and cognitive processing in the rat , 2006, Neuroscience.
[65] P. Jonas,et al. Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks , 2007, Nature Reviews Neuroscience.
[66] A. Grace,et al. Aberrant Hippocampal Activity Underlies the Dopamine Dysregulation in an Animal Model of Schizophrenia , 2007, The Journal of Neuroscience.
[67] W. Schultz. Multiple dopamine functions at different time courses. , 2007, Annual review of neuroscience.
[68] T. Robbins,et al. Differential Roles of Dopamine D1 and D2 Receptors in the Nucleus Accumbens in Attentional Performance on the Five-Choice Serial Reaction Time Task , 2007, Neuropsychopharmacology.
[69] V. Haroutunian,et al. Contribution of Cystine–Glutamate Antiporters to the Psychotomimetic Effects of Phencyclidine , 2008, Neuropsychopharmacology.
[70] N. Swerdlow,et al. Realistic expectations of prepulse inhibition in translational models for schizophrenia research , 2008, Psychopharmacology.
[71] Karl J. Friston,et al. Do patients with schizophrenia exhibit aberrant salience? , 2008, Psychological Medicine.
[72] M. Walker,et al. Review: Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited , 2008, Therapeutic advances in neurological disorders.
[73] F. Georges,et al. Cannabinoid Receptors in the Bed Nucleus of the Stria Terminalis Control Cortical Excitation of Midbrain Dopamine Cells In Vivo , 2008, The Journal of Neuroscience.
[74] Lisa M. Wiedholz,et al. Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and ‘schizophrenia-related’ behaviors , 2008, Molecular Psychiatry.
[75] Reto Meuli,et al. Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients , 2008, Neuropsychopharmacology.
[76] A. Phillips,et al. Neural circuits engaged in ventral hippocampal modulation of dopamine function in medial prefrontal cortex and ventral striatum , 2008, Brain Structure and Function.
[77] A. Grace,et al. Critical Role of the Prefrontal Cortex in the Regulation of Hippocampus–Accumbens Information Flow , 2008, The Journal of Neuroscience.
[78] Alice Alvernhe,et al. Different CA1 and CA3 Representations of Novel Routes in a Shortcut Situation , 2008, The Journal of Neuroscience.
[79] D. Javitt,et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia , 2008, Trends in Neurosciences.
[80] E. Kandel,et al. Modeling cognitive endophenotypes of schizophrenia in mice , 2009, Trends in Neurosciences.
[81] N. Lemon,et al. Locus Coeruleus Activation Facilitates Memory Encoding and Induces Hippocampal LTD that Depends on β-Adrenergic Receptor Activation , 2009, Cerebral cortex.
[82] G. Aston-Jones,et al. Role of the bed nucleus of the stria terminalis in the control of ventral tegmental area dopamine neurons , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[83] R. Palmiter,et al. Disruption of NMDAR-dependent burst firing by dopamine neurons provides selective assessment of phasic dopamine-dependent behavior , 2009, Proceedings of the National Academy of Sciences.
[84] Marie-Claude Asselin,et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. , 2009, Archives of general psychiatry.
[85] Jessica A. Cardin,et al. Driving fast-spiking cells induces gamma rhythm and controls sensory responses , 2009, Nature.
[86] D. Malaspina,et al. Anterior hippocampal and orbitofrontal cortical structural brain abnormalities in association with cognitive deficits in schizophrenia , 2009, Schizophrenia Research.
[87] A. Grace,et al. Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia , 2008, Neurotoxicity Research.
[88] Yiping P. Du,et al. Increased hippocampal, thalamic, and prefrontal hemodynamic response to an urban noise stimulus in schizophrenia. , 2009, The American journal of psychiatry.
[89] Mark A Good,et al. Enhanced long-term and impaired short-term spatial memory in GluA1 AMPA receptor subunit knockout mice: evidence for a dual-process memory model. , 2009, Learning & memory.
[90] K. Deisseroth,et al. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance , 2009, Nature.
[91] ChrisD . Frith,et al. Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia , 2009, Nature Reviews Neuroscience.
[92] Anthony A. Grace,et al. Gestational methylazoxymethanol acetate administration: A developmental disruption model of schizophrenia , 2009, Behavioural Brain Research.
[93] J. Coyle,et al. PAGES_DCNS 46_5.qxd:DCNS#45 , 2010 .
[94] T. Insel,et al. Wesleyan University From the SelectedWorks of Charles A . Sanislow , Ph . D . 2010 Research Domain Criteria ( RDoC ) : Toward a New Classification Framework for Research on Mental Disorders , 2018 .
[95] Christina A. Wilson,et al. Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development. , 2010, Clinical schizophrenia & related psychoses.
[96] S. Haber,et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. , 2010, Archives of general psychiatry.
[97] S. B. Evans,et al. Absence of NMDA receptors in dopamine neurons attenuates dopamine release but not conditioned approach during Pavlovian conditioning , 2010, Proceedings of the National Academy of Sciences.
[98] A. Wagner,et al. The hippocampal formation in schizophrenia. , 2010, The American journal of psychiatry.
[99] A. Heinz,et al. Dopaminergic dysfunction in schizophrenia: salience attribution revisited. , 2010, Schizophrenia bulletin.
[100] Anthony A. Grace,et al. Dopamine System Dysregulation by the Ventral Subiculum as the Common Pathophysiological Basis for Schizophrenia Psychosis, Psychostimulant Abuse, and Stress , 2010, Neurotoxicity Research.
[101] S. Rothman,et al. A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam. , 2011, Journal of neurophysiology.
[102] R. Wise,et al. Linking Context with Reward: A Functional Circuit from Hippocampal CA3 to Ventral Tegmental Area , 2011, Science.
[103] Michael G. Garelick,et al. Activation of Dopamine Neurons is Critical for Aversive Conditioning and Prevention of Generalized Anxiety , 2011, Nature Neuroscience.
[104] A. Arnsten. Catecholamine Influences on Dorsolateral Prefrontal Cortical Networks , 2011, Biological Psychiatry.
[105] S. Ganguly,et al. Effect of ‘chronic’ versus ‘acute’ ketamine administration and its ‘withdrawal’ effect on behavioural alterations in mice: Implications for experimental psychosis , 2011, Behavioural Brain Research.
[106] A. Gamal,et al. Miniaturized integration of a fluorescence microscope , 2011, Nature Methods.
[107] B. Kocsis,et al. Comparison of the effects of acute and chronic administration of ketamine on hippocampal oscillations: relevance for the NMDA receptor hypofunction model of schizophrenia , 2011, Brain Structure and Function.
[108] Paul J. Harrison,et al. Fractionation of Spatial Memory in GRM2/3 (mGlu2/mGlu3) Double Knockout Mice Reveals a Role for Group II Metabotropic Glutamate Receptors at the Interface Between Arousal and Cognition , 2011, Neuropsychopharmacology.
[109] T. Robbins,et al. Selective Remediation of Reversal Learning Deficits in the Neurodevelopmental MAM Model of Schizophrenia by a Novel mGlu5 Positive Allosteric Modulator , 2012, Neuropsychopharmacology.
[110] Masahiko Watanabe,et al. Three Types of Neurochemical Projection from the Bed Nucleus of the Stria Terminalis to the Ventral Tegmental Area in Adult Mice , 2012, The Journal of Neuroscience.
[111] R. Murray,et al. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. , 2012, The American journal of psychiatry.
[112] R. Gruetter,et al. N-Acetylcysteine Normalizes Neurochemical Changes in the Glutathione-Deficient Schizophrenia Mouse Model During Development , 2012, Biological Psychiatry.
[113] K. Deisseroth,et al. Optogenetic investigation of neural circuits underlying brain disease in animal models , 2012, Nature Reviews Neuroscience.
[114] J. Coyle. NMDA receptor and schizophrenia: a brief history. , 2012, Schizophrenia bulletin.
[115] S. Siegel,et al. Subchronic ketamine treatment leads to permanent changes in EEG, cognition and the astrocytic glutamate transporter EAAT2 in mice , 2012, Neurobiology of Disease.
[116] S. Ganguly,et al. Neurochemical and molecular characterization of ketamine-induced experimental psychosis model in mice , 2012, Neuropharmacology.
[117] Anthony A. Grace,et al. Dopamine system dysregulation by the hippocampus: Implications for the pathophysiology and treatment of schizophrenia , 2012, Neuropharmacology.
[118] J. Krystal,et al. Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. , 2012, Schizophrenia bulletin.
[119] Rizwan Ali,et al. N-Acetylcysteine and Metabotropic Glutamate Receptors: Implications for the Treatment of Schizophrenia: A Literature review , 2014, Psychiatric Quarterly.
[120] Isabel Gauthier,et al. Reduced habituation in patients with schizophrenia , 2013, Schizophrenia Research.
[121] S. Williams,et al. Quantifying the Attenuation of the Ketamine Pharmacological Magnetic Resonance Imaging Response in Humans: A Validation Using Antipsychotic and Glutamatergic Agents , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[122] R. Kraftsik,et al. Early-Life Insults Impair Parvalbumin Interneurons via Oxidative Stress: Reversal by N-Acetylcysteine , 2013, Biological Psychiatry.
[123] J. Lindenmayer,et al. Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo , 2013, Schizophrenia Research.
[124] A. Brady,et al. Impairments in set-shifting but not reversal learning in the neonatal ventral hippocampal lesion model of schizophrenia: Further evidence for medial prefrontal deficits , 2013, Behavioural Brain Research.
[125] A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia , 2014, Psychopharmacology.
[126] M. L. Le Pelley,et al. Attention to Irrelevant Cues Is Related to Positive Symptoms in Schizophrenia , 2012, Schizophrenia bulletin.
[127] T. Robbins,et al. CNTRICS final animal model task selection: Control of attention , 2013, Neuroscience & Biobehavioral Reviews.
[128] J. Roiser,et al. Neural and Behavioral Correlates of Aberrant Salience in Individuals at Risk for Psychosis , 2012, Schizophrenia bulletin.
[129] A. Grace,et al. Activation and Inhibition of Neurons in the Hippocampal Ventral Subiculum by Norepinephrine and Locus Coeruleus Stimulation , 2013, Neuropsychopharmacology.
[130] A. Grace,et al. Footshock-induced responses in ventral subiculum neurons are mediated by locus coeruleus noradrenergic afferents , 2013, European Neuropsychopharmacology.
[131] Bita Moghaddam,et al. A Mechanistic Approach to Preventing Schizophrenia in At-Risk Individuals , 2013, Neuron.
[132] Alice M Stamatakis,et al. Distinct extended amygdala circuits for divergent motivational states , 2013, Nature.
[133] B. Kinon,et al. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia , 2013, BMC Psychiatry.
[134] Beatriz Paniagua,et al. Imaging Patients with Psychosis and a Mouse Model Establishes a Spreading Pattern of Hippocampal Dysfunction and Implicates Glutamate as a Driver , 2013, Neuron.
[135] A. R. Cools,et al. Spiraling dopaminergic circuitry from the ventral striatum to dorsal striatum is an effective feed-forward loop , 2013, Neuroscience.
[136] A. Grace,et al. The Infralimbic Cortex Bidirectionally Modulates Mesolimbic Dopamine Neuron Activity via Distinct Neural Pathways , 2013, The Journal of Neuroscience.
[137] J. Rawlins,et al. What causes aberrant salience in schizophrenia? A role for impaired short-term habituation and the GRIA1 (GluA1) AMPA receptor subunit , 2014, Molecular Psychiatry.
[138] Mark D. Morrissey,et al. Parvalbumin and GAD65 Interneuron Inhibition in the Ventral Hippocampus Induces Distinct Behavioral Deficits Relevant to Schizophrenia , 2014, The Journal of Neuroscience.
[139] K. Deisseroth. Circuit dynamics of adaptive and maladaptive behaviour , 2014, Nature.
[140] C. Spencer,et al. Biological Insights From 108 Schizophrenia-Associated Genetic Loci , 2014, Nature.
[141] R. Freedman,et al. Intrinsic hippocampal activity as a biomarker for cognition and symptoms in schizophrenia. , 2014, The American journal of psychiatry.
[142] M. Cuénod,et al. Juvenile Antioxidant Treatment Prevents Adult Deficits in a Developmental Model of Schizophrenia , 2014, Neuron.
[143] N. Swerdlow,et al. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review , 2001, Psychopharmacology.
[144] B. Roth,et al. Chemogenetic tools to interrogate brain functions. , 2014, Annual review of neuroscience.
[145] N. Akaike,et al. Inhibition of Excitatory Synaptic Transmission in Hippocampal Neurons by Levetiracetam Involves Zn2+-Dependent GABA Type A Receptor–Mediated Presynaptic Modulation , 2014, The Journal of Pharmacology and Experimental Therapeutics.
[146] B. Kinon,et al. Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison , 2014, Schizophrenia research and treatment.
[147] O. Howes,et al. Dopaminergic basis of salience dysregulation in psychosis , 2014, Trends in Neurosciences.
[148] Stephan Heckers,et al. Increased hippocampal CA1 cerebral blood volume in schizophrenia , 2014, NeuroImage: Clinical.
[149] D. Lodge,et al. New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways , 2014, Drug design, development and therapy.
[150] J. Feldon,et al. Hyperactivity, decreased startle reactivity, and disrupted prepulse inhibition following disinhibition of the rat ventral hippocampus by the GABAA receptor antagonist picrotoxin , 2001, Psychopharmacology.
[151] B. Kinon,et al. A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. , 2014, BMC psychiatry.
[152] J. Rawlins,et al. Hippocampal synaptic plasticity, spatial memory and anxiety , 2014, Nature Reviews Neuroscience.
[153] M. Chan,et al. N-acetylcysteine modulates hallucinogenic 5-HT2A receptor agonist-mediated responses: Behavioral, molecular, and electrophysiological studies , 2014, Neuropharmacology.
[154] M. Ross,et al. Interneuron precursor transplants in adult hippocampus reverse psychosis-relevant features in a mouse model of hippocampal disinhibition , 2014, Proceedings of the National Academy of Sciences.
[155] N. Swerdlow,et al. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies , 2001, Psychopharmacology.
[156] B. Kinon,et al. A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia , 2014, BMC Psychiatry.
[157] Stephan Heckers,et al. Increased hippocampal blood volume and normal blood flow in schizophrenia , 2015, Psychiatry Research: Neuroimaging.
[158] Renee Hoch,et al. Gamma Rhythms Link Prefrontal Interneuron Dysfunction with Cognitive Inflexibility in Dlx5/6 +/− Mice , 2015, Neuron.
[159] A. Wagner,et al. Synaptic proteins in the hippocampus indicative of increased neuronal activity in CA3 in schizophrenia. , 2015, The American journal of psychiatry.
[160] D. Kullmann,et al. CHAPTER 10:Optogenetic and Chemogenetic Tools for Drug Discovery in Schizophrenia , 2015 .
[161] J. Gallinat,et al. Auditory Mismatch Negativity and Repetition Suppression Deficits in Schizophrenia Explained by Irregular Computation of Prediction Error , 2015, PloS one.
[162] Kenji F. Tanaka,et al. Optogenetic Activation of CA1 Pyramidal Neurons at the Dorsal and Ventral Hippocampus Evokes Distinct Brain-Wide Responses Revealed by Mouse fMRI , 2015, PloS one.
[163] F. Georges,et al. Ventral Subiculum Stimulation Promotes Persistent Hyperactivity of Dopamine Neurons and Facilitates Behavioral Effects of Cocaine. , 2015, Cell reports.
[164] Feng Zhang,et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9 , 2014, Nature Biotechnology.
[165] Xiaojie Gao,et al. Theta oscillations regulate the speed of locomotion via a hippocampus to lateral septum pathway , 2015, Nature Communications.
[166] S. Heckers,et al. GABAergic mechanisms of hippocampal hyperactivity in schizophrenia , 2015, Schizophrenia Research.
[167] D. McKinzie,et al. Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia , 2015, Biological Psychiatry.
[168] D. Murphy,et al. Targeting Glia with N-Acetylcysteine Modulates Brain Glutamate and Behaviors Relevant to Neurodevelopmental Disorders in C57BL/6J Mice , 2015, Front. Behav. Neurosci..
[169] R. Buchert,et al. Aberrant Salience Is Related to Reduced Reinforcement Learning Signals and Elevated Dopamine Synthesis Capacity in Healthy Adults , 2015, The Journal of Neuroscience.
[170] O. Howes,et al. Glutamate and dopamine in schizophrenia: An update for the 21st century , 2015, Journal of psychopharmacology.
[171] Amy L. Griffin,et al. Role of the thalamic nucleus reuniens in mediating interactions between the hippocampus and medial prefrontal cortex during spatial working memory , 2015, Front. Syst. Neurosci..
[172] H. Walter,et al. Validating the construct of aberrant salience in schizophrenia — Behavioral evidence for an automatic process , 2016, Schizophrenia Research: Cognition.
[173] A. Grace,et al. The Nucleus Reuniens of the Midline Thalamus Gates Prefrontal-Hippocampal Modulation of Ventral Tegmental Area Dopamine Neuron Activity , 2016, The Journal of Neuroscience.
[174] C. Kellendonk,et al. Using human brain imaging studies as a guide toward animal models of schizophrenia , 2016, Neuroscience.
[175] M. Owen,et al. Schizophrenia , 2016, The Lancet.
[176] E. Kandel,et al. Dopamine release from the locus coeruleus to the dorsal hippocampus promotes spatial learning and memory , 2016, Proceedings of the National Academy of Sciences.
[177] Stephan Heckers,et al. Hippocampal arterial cerebral blood volume in early psychosis , 2016, Psychiatry Research: Neuroimaging.
[178] R. Gur,et al. Early interventions in risk groups for schizophrenia: what are we waiting for? , 2016, npj Schizophrenia.
[179] Linde Boekhoudt,et al. Chemogenetic activation of dopamine neurons in the ventral tegmental area, but not substantia nigra, induces hyperactivity in rats , 2016, European Neuropsychopharmacology.
[180] R. Morris,et al. Locus coeruleus and dopaminergic consolidation of everyday memory , 2016, Nature.
[181] Amy L. Griffin,et al. Ventral Midline Thalamus Is Critical for Hippocampal–Prefrontal Synchrony and Spatial Working Memory , 2016, The Journal of Neuroscience.
[182] N. Swerdlow,et al. Sensorimotor gating of the startle reflex: what we said 25 years ago, what has happened since then, and what comes next , 2016, Journal of psychopharmacology.
[183] M. Roesch,et al. Neurophysiology of Reward-Guided Behavior: Correlates Related to Predictions, Value, Motivation, Errors, Attention, and Action. , 2016, Current topics in behavioral neurosciences.
[184] P. Veinante,et al. Afferents to anterior cingulate areas 24a and 24b and midcingulate areas 24a′ and 24b′ in the mouse , 2016, Brain Structure and Function.
[185] M. Kuśmider,et al. Effect of clozapine on ketamine-induced deficits in attentional set shift task in mice , 2017, Psychopharmacology.
[186] Michela Gallagher,et al. Targeting Neural Hyperactivity as a Treatment to Stem Progression of Late-Onset Alzheimer’s Disease , 2017, Neurotherapeutics.
[187] H. Moore,et al. Pathway-Specific Dopamine Abnormalities in Schizophrenia , 2017, Biological Psychiatry.
[188] T. Simuni,et al. Pimavanserin, a novel antipsychotic for management of Parkinson’s disease psychosis , 2017, Expert review of clinical pharmacology.
[189] P. Veinante,et al. Efferents of anterior cingulate areas 24a and 24b and midcingulate areas 24aʹ and 24bʹ in the mouse , 2017, Brain Structure and Function.
[190] Pablo E. Jercog,et al. Neural ensemble dynamics underlying a long-term associative memory , 2017, Nature.
[191] Ericka L. Crouse,et al. Pimavanserin: A Novel Antipsychotic for Parkinson’s Disease Psychosis , 2017, The Annals of pharmacotherapy.
[192] Tobias Bast,et al. Hippocampal Neural Disinhibition Causes Attentional and Memory Deficits , 2016, Cerebral cortex.
[193] T. Bast,et al. Cognitive deficits caused by prefrontal cortical and hippocampal neural disinhibition , 2017, British journal of pharmacology.
[194] Karl Deisseroth,et al. Coordination of Brain-Wide Activity Dynamics by Dopaminergic Neurons , 2017, Neuropsychopharmacology.
[195] J. E. Iglesias,et al. Progression from selective to general involvement of hippocampal subfields in schizophrenia , 2016, Molecular Psychiatry.
[196] F. Liu,et al. Dynamic ErbB4 Activity in Hippocampal-Prefrontal Synchrony and Top-Down Attention in Rodents , 2018, Neuron.
[197] P. Fletcher,et al. Brain responses to different types of salience in antipsychotic naïve first episode psychosis: An fMRI study , 2018, bioRxiv.
[198] A. Grace,et al. Medial septum activation produces opposite effects on dopamine neuron activity in the ventral tegmental area and substantia nigra in MAM vs. normal rats , 2018, npj Schizophrenia.
[199] S. Dursun,et al. Multidimensional Connectomics and Treatment-Resistant Schizophrenia: Linking Phenotypic Circuits to Targeted Therapeutics , 2018, Front. Psychiatry.
[200] S. Heckers,et al. Regionally specific volume deficits along the hippocampal long axis in early and chronic psychosis , 2018, NeuroImage: Clinical.
[201] F. Tarazi,et al. Pimavanserin: novel pharmacotherapy for Parkinson’s disease psychosis , 2018, Expert opinion on drug discovery.
[202] Alan Carleton,et al. Restoring wild-type-like CA1 network dynamics and behavior during adulthood in a mouse model of schizophrenia , 2018, Nature Neuroscience.
[203] J. Levitt,et al. Functional dysconnectivity of the limbic loop of frontostriatal circuits in first‐episode, treatment‐naive schizophrenia , 2018, Human brain mapping.
[204] Evan Z. Macosko,et al. Molecular Diversity and Specializations among the Cells of the Adult Mouse Brain , 2018, Cell.
[205] Thomas Hainmueller,et al. Parallel emergence of stable and dynamic memory engrams in the hippocampus , 2018, Nature.
[206] Brain responses to different types of salience in antipsychotic naïve first episode psychosis: An fMRI study , 2018 .
[207] H. Akbari,et al. Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial , 2017, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[208] A. Egerton,et al. Effects of N-acetylcysteine on brain glutamate levels and resting perfusion in schizophrenia , 2018, Psychopharmacology.
[209] E. Boyden,et al. Optogenetic induction of the schizophrenia-related endophenotype of ventral hippocampal hyperactivity causes rodent correlates of positive and cognitive symptoms , 2018, Scientific Reports.
[210] Allan R. Jones,et al. Shared and distinct transcriptomic cell types across neocortical areas , 2018, Nature.
[211] A. Grace,et al. Medial septum differentially regulates dopamine neuron activity in the rat ventral tegmental area and substantia nigra via distinct pathways , 2018, Neuropsychopharmacology.
[212] D. Kätzel,et al. Schizophrenia-related cognitive dysfunction in the Cyclin-D2 knockout mouse model of ventral hippocampal hyperactivity , 2018, bioRxiv.
[213] Steven C. R. Williams,et al. Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects , 2018, Psychopharmacology.
[214] R. Sprengel,et al. Hippocampal–prefrontal coherence mediates working memory and selective attention at distinct frequency bands and provides a causal link between schizophrenia and its risk gene GRIA1 , 2019, Translational Psychiatry.
[215] T. Amelsvoort,et al. Efficacy and tolerability of riluzole in psychiatric disorders: A systematic review and preliminary meta-analysis , 2019, Psychiatry Research.
[216] I. Sommer,et al. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis , 2019, Psychological Medicine.
[217] Yi Zhou,et al. NMDAR Hypofunction Animal Models of Schizophrenia , 2019, Front. Mol. Neurosci..
[218] Mattia Veronese,et al. Mesolimbic Dopamine Function Is Related to Salience Network Connectivity: An Integrative Positron Emission Tomography and Magnetic Resonance Study , 2019, Biological Psychiatry.
[219] R. Sprengel,et al. Attenuation of Novelty-Induced Hyperactivity of Gria1-/- Mice by Cannabidiol and Hippocampal Inhibitory Chemogenetics , 2019, Front. Pharmacol..
[220] Julia L. Fouty,et al. Anterior Cingulate Cortex and Ventral Hippocampal Inputs to the Basolateral Amygdala Selectively Control Generalized Fear , 2019, The Journal of Neuroscience.
[221] S. Heckers,et al. Disrupted Habituation in the Early Stage of Psychosis. , 2019, Biological psychiatry. Cognitive neuroscience and neuroimaging.
[222] S. Heckers,et al. Hyperactivity and Reduced Activation of Anterior Hippocampus in Early Psychosis. , 2019, The American journal of psychiatry.
[223] A. Egerton,et al. Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications , 2019, Psychopharmacology.
[224] P. Caroni,et al. Long-Lasting Rescue of Network and Cognitive Dysfunction in a Genetic Schizophrenia Model , 2019, Cell.
[225] M. Cuénod,et al. MMP9/RAGE pathway overactivation mediates redox dysregulation and neuroinflammation, leading to inhibitory/excitatory imbalance: a reverse translation study in schizophrenia patients , 2019, Molecular Psychiatry.
[226] Allan R. Jones,et al. Conserved cell types with divergent features in human versus mouse cortex , 2019, Nature.
[227] Lei Chang,et al. Anterior Cingulate Cortex to Ventral Hippocampus Circuit Mediates Contextual Fear Generalization , 2019, The Journal of Neuroscience.
[228] A. Carvalho,et al. The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta‐review of meta‐analyses of randomized controlled trials , 2019, World psychiatry : official journal of the World Psychiatric Association.
[229] A. Harris,et al. Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia , 2019, The Australian and New Zealand journal of psychiatry.
[230] Kim David Ferrari,et al. Rapid Reconfiguration of the Functional Connectome after Chemogenetic Locus Coeruleus Activation , 2019, Neuron.
[231] Valerio Zerbi,et al. Rapid Reconfiguration of the Functional Connectome after Chemogenetic Locus Coeruleus Activation , 2019, Neuron.